Donna M. O'Neill
Chief Tech/Sci/R&D Officer at Aviv Healthcare Properties LP
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Steven Insoft | M | 60 |
Aviv Healthcare Properties LP
Aviv Healthcare Properties LP Real Estate Investment TrustsFinance Aviv Healthcare Properties LP provides real estate services. It engages in owning and leasing of skilled nursing facilities across the United States. The company was founded by Craig M. Bernfield on March 4, 2005 and is headquartered in Chicago, IL. | 11 years |
Craig M. Bernfield | M | 63 |
Aviv Healthcare Properties LP
Aviv Healthcare Properties LP Real Estate Investment TrustsFinance Aviv Healthcare Properties LP provides real estate services. It engages in owning and leasing of skilled nursing facilities across the United States. The company was founded by Craig M. Bernfield on March 4, 2005 and is headquartered in Chicago, IL. | 19 years |
Mark L. Wetzel | M | 66 |
Aviv Healthcare Properties LP
Aviv Healthcare Properties LP Real Estate Investment TrustsFinance Aviv Healthcare Properties LP provides real estate services. It engages in owning and leasing of skilled nursing facilities across the United States. The company was founded by Craig M. Bernfield on March 4, 2005 and is headquartered in Chicago, IL. | 3 years |
Susan Lichtenstein | F | 67 |
Aviv Healthcare Properties LP
Aviv Healthcare Properties LP Real Estate Investment TrustsFinance Aviv Healthcare Properties LP provides real estate services. It engages in owning and leasing of skilled nursing facilities across the United States. The company was founded by Craig M. Bernfield on March 4, 2005 and is headquartered in Chicago, IL. | - |
Norman R. Bobins | M | 81 |
Aviv Healthcare Properties LP
Aviv Healthcare Properties LP Real Estate Investment TrustsFinance Aviv Healthcare Properties LP provides real estate services. It engages in owning and leasing of skilled nursing facilities across the United States. The company was founded by Craig M. Bernfield on March 4, 2005 and is headquartered in Chicago, IL. | 3 years |
Ben W. Perks | M | 81 |
Aviv Healthcare Properties LP
Aviv Healthcare Properties LP Real Estate Investment TrustsFinance Aviv Healthcare Properties LP provides real estate services. It engages in owning and leasing of skilled nursing facilities across the United States. The company was founded by Craig M. Bernfield on March 4, 2005 and is headquartered in Chicago, IL. | 9 years |
Alan Edward Goldberg | M | 70 |
Aviv Healthcare Properties LP
Aviv Healthcare Properties LP Real Estate Investment TrustsFinance Aviv Healthcare Properties LP provides real estate services. It engages in owning and leasing of skilled nursing facilities across the United States. The company was founded by Craig M. Bernfield on March 4, 2005 and is headquartered in Chicago, IL. | 14 years |
James Russell Triedman | M | 54 |
Aviv Healthcare Properties LP
Aviv Healthcare Properties LP Real Estate Investment TrustsFinance Aviv Healthcare Properties LP provides real estate services. It engages in owning and leasing of skilled nursing facilities across the United States. The company was founded by Craig M. Bernfield on March 4, 2005 and is headquartered in Chicago, IL. | 14 years |
Sharon O'Keefe | F | 72 |
Aviv Healthcare Properties LP
Aviv Healthcare Properties LP Real Estate Investment TrustsFinance Aviv Healthcare Properties LP provides real estate services. It engages in owning and leasing of skilled nursing facilities across the United States. The company was founded by Craig M. Bernfield on March 4, 2005 and is headquartered in Chicago, IL. | 3 years |
Mark McClellan | M | 60 |
Aviv Healthcare Properties LP
Aviv Healthcare Properties LP Real Estate Investment TrustsFinance Aviv Healthcare Properties LP provides real estate services. It engages in owning and leasing of skilled nursing facilities across the United States. The company was founded by Craig M. Bernfield on March 4, 2005 and is headquartered in Chicago, IL. | 3 years |
James Roth | M | 66 |
Aviv Healthcare Properties LP
Aviv Healthcare Properties LP Real Estate Investment TrustsFinance Aviv Healthcare Properties LP provides real estate services. It engages in owning and leasing of skilled nursing facilities across the United States. The company was founded by Craig M. Bernfield on March 4, 2005 and is headquartered in Chicago, IL. | 3 years |
Joshua J. Kochek | M | 46 | 16 years | |
Steven R. Levin | M | 66 | 13 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Jack J. Kogut | M | 77 |
Northfield Laboratories, Inc.
Northfield Laboratories, Inc. BiotechnologyHealth Technology The Company's principal activity is to develop, manufacture, market and distribute a hemoglobin-based blood substitute product. The Company's product, PolyHeme(R) blood substitute, provides an alternative to transfused blood for use in the treatment of acute blood loss. The company uses a proprietary process of separation, filtration, chemical modification purification and formulation to produce PolyHeme. PolyHeme is designed to avoid potential undesirable effects such as vasoconstriction, kidney dysfunction, liver dysfunction and gastrointestinal distress. Clinical trials of PolyHeme have been conducted at multiple locations in the United States. The company has entered into license agreements with Pfizer Inc and Hemocare Ltd an Israeli corporation to develop manufacture and distribute PolyHeme in certain European, Middle Eastern and African countries. The Company is in development stage. | 15 years |
James H. Lyman | M | 65 | 1 years | |
Bob Demarest Lindsay | M | 68 | - | |
Michael Dees | M | 50 | - | |
John J. Hinds | M | - |
Northfield Laboratories, Inc.
Northfield Laboratories, Inc. BiotechnologyHealth Technology The Company's principal activity is to develop, manufacture, market and distribute a hemoglobin-based blood substitute product. The Company's product, PolyHeme(R) blood substitute, provides an alternative to transfused blood for use in the treatment of acute blood loss. The company uses a proprietary process of separation, filtration, chemical modification purification and formulation to produce PolyHeme. PolyHeme is designed to avoid potential undesirable effects such as vasoconstriction, kidney dysfunction, liver dysfunction and gastrointestinal distress. Clinical trials of PolyHeme have been conducted at multiple locations in the United States. The company has entered into license agreements with Pfizer Inc and Hemocare Ltd an Israeli corporation to develop manufacture and distribute PolyHeme in certain European, Middle Eastern and African countries. The Company is in development stage. | - |
Mark Parrell | M | 57 | 2 years | |
Zev Karkomi | M | 100 | - | |
Samuel H. Kovitz | M | 61 | 10 years | |
Ari Ryan | M | 48 | - | |
Alan L. Heller | M | 70 |
Northfield Laboratories, Inc.
Northfield Laboratories, Inc. BiotechnologyHealth Technology The Company's principal activity is to develop, manufacture, market and distribute a hemoglobin-based blood substitute product. The Company's product, PolyHeme(R) blood substitute, provides an alternative to transfused blood for use in the treatment of acute blood loss. The company uses a proprietary process of separation, filtration, chemical modification purification and formulation to produce PolyHeme. PolyHeme is designed to avoid potential undesirable effects such as vasoconstriction, kidney dysfunction, liver dysfunction and gastrointestinal distress. Clinical trials of PolyHeme have been conducted at multiple locations in the United States. The company has entered into license agreements with Pfizer Inc and Hemocare Ltd an Israeli corporation to develop manufacture and distribute PolyHeme in certain European, Middle Eastern and African countries. The Company is in development stage. | 3 years |
Laurel A. Omert | M | 67 |
Northfield Laboratories, Inc.
Northfield Laboratories, Inc. BiotechnologyHealth Technology The Company's principal activity is to develop, manufacture, market and distribute a hemoglobin-based blood substitute product. The Company's product, PolyHeme(R) blood substitute, provides an alternative to transfused blood for use in the treatment of acute blood loss. The company uses a proprietary process of separation, filtration, chemical modification purification and formulation to produce PolyHeme. PolyHeme is designed to avoid potential undesirable effects such as vasoconstriction, kidney dysfunction, liver dysfunction and gastrointestinal distress. Clinical trials of PolyHeme have been conducted at multiple locations in the United States. The company has entered into license agreements with Pfizer Inc and Hemocare Ltd an Israeli corporation to develop manufacture and distribute PolyHeme in certain European, Middle Eastern and African countries. The Company is in development stage. | 4 years |
Edward C. Wood | M | 79 |
Northfield Laboratories, Inc.
Northfield Laboratories, Inc. BiotechnologyHealth Technology The Company's principal activity is to develop, manufacture, market and distribute a hemoglobin-based blood substitute product. The Company's product, PolyHeme(R) blood substitute, provides an alternative to transfused blood for use in the treatment of acute blood loss. The company uses a proprietary process of separation, filtration, chemical modification purification and formulation to produce PolyHeme. PolyHeme is designed to avoid potential undesirable effects such as vasoconstriction, kidney dysfunction, liver dysfunction and gastrointestinal distress. Clinical trials of PolyHeme have been conducted at multiple locations in the United States. The company has entered into license agreements with Pfizer Inc and Hemocare Ltd an Israeli corporation to develop manufacture and distribute PolyHeme in certain European, Middle Eastern and African countries. The Company is in development stage. | 4 years |
Steven E. Fleck | M | - |
Northfield Laboratories, Inc.
Northfield Laboratories, Inc. BiotechnologyHealth Technology The Company's principal activity is to develop, manufacture, market and distribute a hemoglobin-based blood substitute product. The Company's product, PolyHeme(R) blood substitute, provides an alternative to transfused blood for use in the treatment of acute blood loss. The company uses a proprietary process of separation, filtration, chemical modification purification and formulation to produce PolyHeme. PolyHeme is designed to avoid potential undesirable effects such as vasoconstriction, kidney dysfunction, liver dysfunction and gastrointestinal distress. Clinical trials of PolyHeme have been conducted at multiple locations in the United States. The company has entered into license agreements with Pfizer Inc and Hemocare Ltd an Israeli corporation to develop manufacture and distribute PolyHeme in certain European, Middle Eastern and African countries. The Company is in development stage. | 7 years |
David J. Smith | M | 43 | 2 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 27 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Donna M. O'Neill
- Personal Network